Barclays PLC Fate Therapeutics Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 424,277 shares of FATE stock, worth $712,785. This represents 0.0% of its overall portfolio holdings.

Number of Shares

424,277

Previous 424,277 -0.0%

Holding current value

$712,785

Previous $1.49 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.12 - $5.57 $940,333 - $1.68 Million	301,389 Added 245.26%	424,277 $1.49 Million
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $656,417 - $1.43 Million	-201,355 Reduced 62.1%	122,888 $403,000
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $124,367 - $293,352	-35,132 Reduced 9.78%	324,243 $2.38 Million
Q4 2023 Feb 15, 2024	BUY	$1.65 - $3.94 $397,029 - $948,058	240,624 Added 202.63%	359,375 $1.34 Million
Q3 2023 Nov 07, 2023	SELL	$2.02 - $5.04 $727,902 - $1.82 Million	-360,348 Reduced 75.21%	118,751 $252,000
Q2 2023 Aug 03, 2023	SELL	$4.76 - $6.59 $103,401 - $143,154	-21,723 Reduced 4.34%	479,099 $2.28 Million
Q1 2023 May 04, 2023	BUY	$4.24 - $11.12 $1 Million - $2.63 Million	236,947 Added 89.8%	500,822 $2.86 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $837,705 - $2.02 Million	84,960 Added 47.49%	263,875 $2.66 Million
Q3 2022 Nov 03, 2022	BUY	$21.04 - $36.06 $3.33 Million - $5.7 Million	158,098 Added 759.47%	178,915 $4.01 Million
Q2 2022 Aug 12, 2022	SELL	$17.78 - $42.39 $10,330 - $24,628	-581 Reduced 2.72%	20,817 $516,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $2.52 Million - $5.11 Million	-84,820 Reduced 79.85%	21,398 $830,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $2.46 Million - $3.31 Million	51,470 Added 94.01%	106,218 $6.22 Million
Q3 2021 Nov 09, 2021	BUY	$59.27 - $95.73 $723,331 - $1.17 Million	12,204 Added 28.69%	54,748 $3.24 Million
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $4.52 Million - $6.22 Million	-67,235 Reduced 61.25%	42,544 $3.69 Million
Q1 2021 May 13, 2021	SELL	$72.16 - $117.4 $1.45 Million - $2.36 Million	-20,070 Reduced 15.46%	109,779 $9.05 Million
Q4 2020 Feb 11, 2021	SELL	$38.09 - $100.95 $1.11 Million - $2.94 Million	-29,142 Reduced 18.33%	129,849 $11.8 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $679,268 - $904,648	22,337 Added 16.35%	158,991 $6.36 Million
Q2 2020 Aug 12, 2020	BUY	$20.21 - $35.23 $547,327 - $954,098	27,082 Added 24.72%	136,654 $4.69 Million
Q1 2020 May 13, 2020	BUY	$17.28 - $31.88 $845,320 - $1.56 Million	48,919 Added 80.65%	109,572 $2.43 Million
Q4 2019 Feb 10, 2020	BUY	$13.39 - $20.73 $73,216 - $113,351	5,468 Added 9.91%	60,653 $1.19 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $329,928 - $479,857	-21,327 Reduced 27.87%	55,185 $858,000
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $682,250 - $893,350	43,706 Added 133.23%	76,512 $1.55 Million
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $4,563 - $6,492	347 Added 1.07%	32,806 $576,000
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $12,260 - $18,134	-1,068 Reduced 3.19%	32,459 $416,000
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $228,243 - $424,924	26,085 Added 350.51%	33,527 $547,000
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $104,085 - $153,173	-11,363 Reduced 60.43%	7,442 $85,000
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $79,235 - $173,185	12,577 Added 201.94%	18,805 $184,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $13,967 - $23,538	3,545 Added 132.13%	6,228 $38,000
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $6,975 - $11,563	2,683	2,683 $11,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account